About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

Barclays said it has moved to a tactical neutral stance on risk assets, despite current valuations are becoming more attractive.

2026-11-09

Barclays said it has moved to a tactical neutral stance on risk assets, despite current valuations are becoming more attractive.

Other News
2026-11-09

In an interview with TechCrunch, Jeffrey Sonnenfeld, a professor at Yale School of Management and founder of the Yale Institute for CEO Leadership, stated that Huang's chances of continuing as Nvidia CEO are approximately 50%. Sonnenfeld believes tha

In an interview with TechCrunch, Jeffrey Sonnenfeld, a professor at Yale School of Management and founder of the Yale Institute for CEO Leadership, stated that Huang's chances of continuing as Nvidia CEO are approximately 50%. Sonnenfeld believes that Huang's recent admission of infidelity and apology to his family, employees, and board has escalated into a matter of corporate governance and leadership reputation, potentially undermining employee trust in his leadership abilities. He characterized the incident as a misjudgment and noted that Nvidia's board has launched an independent investigation. Although the board has stated that Huang will continue as CEO and cooperate with the investigation, the investigation's findings and subsequent governance arrangements could still affect his position. Sonnenfeld also suggested a possibility: Huang could retain the CEO title but gradually delegate some day-to-day management responsibilities to other executives. Nvidia has not yet announced a succession plan. Given Huang's long-standing leadership in the company's strategy, product roadmap, and organizational management, the stability of his position is also crucial to Nvidia's future management succession and decision-making continuity.
2026-11-09

A-share innovative drug concept stocks fluctuated higher during the session, with Lemei Pharmaceutical rising by more than 15%, and Zhaoyan New Drug, Medicilon, Chengdu Pioneer, Rongchang Bio and Nearshore Protein among the top gainers.

A-share innovative drug concept stocks fluctuated higher during the session, with Lemei Pharmaceutical rising by more than 15%, and Zhaoyan New Drug, Medicilon, Chengdu Pioneer, Rongchang Bio and Nearshore Protein among the top gainers.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.